| 1 |
Liu R, Yang L, Jiang T, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hao H, Hu L, Gao Y, Xu M, Chen X, Yi W, Li M, Xie Y. Hepatitis B core-related antigen serum levels may be a predictor of acute flare of chronic hepatitis B among pregnant women in the immune-tolerant phase of chronic HBV infection after short-course antiviral therapy. Virulence 2023;14:2186335. [PMID: 36864005 DOI: 10.1080/21505594.2023.2186335] [Reference Citation Analysis]
|
| 2 |
Zhang Q, Liu X, Pang X, Wang H, Du J, Ren H, Hu P. Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels. Cytokine 2023;164:156140. [PMID: 36738524 DOI: 10.1016/j.cyto.2023.156140] [Reference Citation Analysis]
|
| 3 |
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Nan Y, Zheng H, Liu J, Wei L, Feng B. HBsAg ≤ 135 IU/mL or HBcrAg ≤ 3.6 logU/mL was associated with HBsAg loss after nucleos(t)ide analogue cessation.. [DOI: 10.21203/rs.3.rs-2611117/v1] [Reference Citation Analysis]
|
| 4 |
Huang C, Yang C, Su P, Chen Y, Huang S, Yen H. Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy. Biomedicines 2023;11:752. [DOI: 10.3390/biomedicines11030752] [Reference Citation Analysis]
|
| 5 |
Tseng TN, Jeng WJ, Hu TH, Wang JH, Hung CH, Lu SN, Chen CH. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation. J Antimicrob Chemother 2023;78:436-9. [PMID: 36478233 DOI: 10.1093/jac/dkac409] [Reference Citation Analysis]
|
| 6 |
Chen CH, Jeng WJ, Hu TH, Liu YC, Wang JH, Hung CH, Lu SN, Chien RN. HBV relapse rates in patients who discontinue tenofovir disoproxil fumarate with or without switching to tenofovir alafenamide. Dig Liver Dis 2023:S1590-8658(23)00165-2. [PMID: 36737315 DOI: 10.1016/j.dld.2023.01.154] [Reference Citation Analysis]
|
| 7 |
Chiu SM, Chang KC, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation. Dig Dis Sci 2023;68:665-75. [PMID: 35976597 DOI: 10.1007/s10620-022-07657-8] [Reference Citation Analysis]
|
| 8 |
Cheng PN, Liu CJ, Chen CY, Tseng KC, Lo CC, Peng CY, Lin CL, Chiu HC, Chiu YC, Chen PJ. Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial. Clin Gastroenterol Hepatol 2022;20:2800-8. [PMID: 34864158 DOI: 10.1016/j.cgh.2021.11.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Liem KS, Chi H, Fung S, Wong DK, Yim C, Noureldin S, Chen J, de Man RA, Sarowar A, Feld JJ, Hansen BE, Hou J, Peng J, Janssen HLA. Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B. J Viral Hepat 2022;29:986-93. [PMID: 36048970 DOI: 10.1111/jvh.13742] [Reference Citation Analysis]
|
| 10 |
Tseng C, Chen T, Wu J, Lee T, Borghi JA, Lin J, Nguyen MH, Hsu Y. Serious adverse events after cessation of nucleos(t)ide analogues in individuals with chronic hepatitis B: A systematic review and meta-analysis. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100617] [Reference Citation Analysis]
|
| 11 |
Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. The Role of Off-Therapy Viral Kinetics in the Timing and Severity of Flares in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol 2022:S1542-3565(22)00817-5. [PMID: 36038130 DOI: 10.1016/j.cgh.2022.08.021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 12 |
Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2022;71:1629-41. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 13 |
Fang HW, Yen YH, Hung CH, Wang JH, Hu TH, Lu SN, Chen CH. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir. Dig Dis Sci 2022;67:3402-11. [PMID: 34241753 DOI: 10.1007/s10620-021-07128-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Wang F, Zhou J, Li L, Wang M, Tao Y, Wang Y, Zhang D, Chen E. Serum Pregenomic RNA Combined With Hepatitis B Core-Related Antigen Helps Predict the Risk of Virological Relapse After Discontinuation of Nucleos(t)ide Analogs in Patients With Chronic Hepatitis B. Front Microbiol 2022;13:901233. [DOI: 10.3389/fmicb.2022.901233] [Reference Citation Analysis]
|
| 15 |
Tseng TN, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse. Viruses 2022;14. [PMID: 35746660 DOI: 10.3390/v14061189] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Liu YC, Jeng WJ, Peng CW, Chien RN, Liaw YF. Off-tenofovir hepatitis flares in HBeAg-negative patients occur earlier, more frequent and severe than those off-entecavir therapies. Liver Int 2022;42:551-60. [PMID: 34936719 DOI: 10.1111/liv.15140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 18 |
Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, Papatheodoridi M, Lens S, Wong G, Brakenhoff SM, Chien RN, Feld J, Sonneveld MJ, Chan HLY, Forns X, Papatheodoridis GV, Vanwolleghem T, Yuen MF, Hsu YC, Kao JH, Cornberg M, Hansen BE, Jeng WJ, Janssen HLA; RETRACT-B Study Group. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). Gastroenterology 2022;162:757-771.e4. [PMID: 34762906 DOI: 10.1053/j.gastro.2021.11.002] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
|
| 19 |
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, Lin CS, Deng H, Zhao ZX, Xie DY, Gao ZL, Peng L. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021;9:313-22. [PMID: 34567563 DOI: 10.1093/gastro/goab013] [Reference Citation Analysis]
|
| 20 |
Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 21 |
Huang PY, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients. J Viral Hepat 2021;28:1141-9. [PMID: 33932245 DOI: 10.1111/jvh.13528] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 22 |
Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 23 |
Gao L, Hu Y, Shi X, Li X, Zhang D, Ren H. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Ann Hepatol 2020;19:329-34. [PMID: 31884016 DOI: 10.1016/j.aohep.2019.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 24 |
Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 25 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Yeh ML, Huang JF, Yu ML, Chuang WL. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol 2021;15:427-35. [PMID: 33338385 DOI: 10.1080/17474124.2021.1866985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 27 |
Kuo YH, Wang JH, Hung CH, Lu SN, Hu TH, Chen CH. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation. Hepatol Int 2021;15:301-9. [PMID: 33665773 DOI: 10.1007/s12072-021-10159-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 28 |
Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Huang Y, Nan Y, Zheng H, Feng B. HBeAg-positive patients with HBsAg < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856-67. [PMID: 34292372 DOI: 10.1007/s00535-021-01812-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 29 |
Lin C, Kao J. Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection. Hepatitis B Virus and Liver Disease 2021. [DOI: 10.1007/978-981-16-3615-8_10] [Reference Citation Analysis]
|
| 30 |
Chiu SM, Kuo YH, Wang JH, Hung CH, Hu TH, Lu SN, Chen CH. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy. Clin Gastroenterol Hepatol 2020;18:2989-2997.e3. [PMID: 32353534 DOI: 10.1016/j.cgh.2020.04.048] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 31 |
Tseng TN, Hu TH, Wang JH, Kuo YH, Hung CH, Lu SN, Jeng WJ, Chen CH. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL. Clin Gastroenterol Hepatol 2020;18:2803-2812.e2. [PMID: 32360818 DOI: 10.1016/j.cgh.2020.04.037] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
|
| 32 |
Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 33 |
Yeh ML, Huang CF, Huang CI, Holmes JA, Hsieh MH, Tsai YS, Liang PC, Tsai PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chung RT, Yu ML. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. J Hepatol 2020;73:62-71. [PMID: 32061869 DOI: 10.1016/j.jhep.2020.01.027] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 34 |
Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 35 |
Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat 2020;27:118-26. [PMID: 31562748 DOI: 10.1111/jvh.13211] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 36 |
Chen CH, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019;219:1624-1633. [PMID: 30689910 DOI: 10.1093/infdis/jiy697] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 37 |
O'Neil CR, Congly SE, Rose MS, Lee SS, Borman MA, Charlton CL, Osiowy C, Swain MG, Burak KW, Coffin CS. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers. Ann Hepatol 2018;17:232-41. [PMID: 31097238 DOI: 10.5604/01.3001.0010.8640] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 38 |
Chen C, Hu T, Wang J, Lai H, Hung C, Lu S, Peng C. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatol Int 2020;14:317-25. [DOI: 10.1007/s12072-019-09991-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 39 |
Ma TL, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment. PLoS One 2019;14:e0222221. [PMID: 31584951 DOI: 10.1371/journal.pone.0222221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 40 |
Jeng WJ, Hsu YC, Su TH, Chen CH. Letter to the Editor: Deliberations More Than a Cut-off Hepatitis B Surface Antigen Value for Nucleos(t)ide Analogue Cessation. Hepatology 2019;70:1488-9. [PMID: 30793771 DOI: 10.1002/hep.30576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 41 |
Abdurakhmanov D, Ibragimov E, Rozina T, Nikulkina E, Mazurchik N. HBsAg levels as a guide for finite treatment duration of chronic hepatitis B. Clin Res Hepatol Gastroenterol 2019;43:e73-5. [PMID: 30670355 DOI: 10.1016/j.clinre.2018.12.007] [Reference Citation Analysis]
|
| 42 |
Liu J, Li T, Zhang L, Xu A. Reply. Hepatology 2019;70:1489-90. [PMID: 30779450 DOI: 10.1002/hep.30573] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 43 |
Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis 2019;86:201-7. [PMID: 31394205 DOI: 10.1016/j.ijid.2019.07.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 44 |
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 2019;25:93-159. [PMID: 31185710 DOI: 10.3350/cmh.2019.1002] [Cited by in Crossref: 113] [Cited by in F6Publishing: 124] [Article Influence: 28.3] [Reference Citation Analysis]
|
| 45 |
Kuo MT, Hu TH, Hung CH, Wang JH, Lu SN, Tsai KL, Chen CH. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019;49:218-28. [PMID: 30484881 DOI: 10.1111/apt.15053] [Cited by in Crossref: 40] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 46 |
Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther 2019;49:107-15. [PMID: 30450681 DOI: 10.1111/apt.15058] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 14.3] [Reference Citation Analysis]
|
| 47 |
Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 48 |
Kuo MT, Tseng PL, Chou YP, Chang KC, Tsai MC, Kuo YH, Hu TH, Hung CH, Wang JH, Lu SN, Chen CH. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy. J Gastroenterol Hepatol 2018;33:1766-72. [PMID: 29514418 DOI: 10.1111/jgh.14142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Raad II, Chaftari AM, Torres HA, Ayoub EM, Narouz LI, Bartek J, Hachem R. Challenge of hepatitis C in Egypt and hepatitis B in Mauritania. World J Hepatol 2018;10:549-57. [PMID: 30310533 DOI: 10.4254/wjh.v10.i9.549] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 50 |
Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis 2018;19:561-71. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 51 |
Xu WX, Zhang Q, Zhu X, Lin CS, Chen YM, Deng H, Mei YY, Zhao ZX, Xie DY, Gao ZL, Xie C, Peng L. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Can J Gastroenterol Hepatol 2018;2018:1817680. [PMID: 29862225 DOI: 10.1155/2018/1817680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 52 |
Chen CH, Hsu YC, Lu SN, Hung CH, Wang JH, Lee CM, Hu TH. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients. J Viral Hepat 2018;25:590-7. [PMID: 29274189 DOI: 10.1111/jvh.12851] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 53 |
Hsu WF, Chen CF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Wang HW, Huang GT, Peng CY. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy. Liver Int 2018;38:627-35. [PMID: 28857411 DOI: 10.1111/liv.13564] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 54 |
Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 9.4] [Reference Citation Analysis]
|
| 55 |
Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018;24:997-1003. [PMID: 29288020 DOI: 10.1016/j.cmi.2017.12.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
|
| 56 |
Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 57 |
Hsu YC, Mo LR, Chang CY, Wu MS, Yang TH, Kao JH, Chen CC, Tseng CH, Tai CM, Lin CW, Wu CY, Lin JT. Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy. J Gastroenterol Hepatol 2017;32:1512-9. [PMID: 28122151 DOI: 10.1111/jgh.13728] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 58 |
Brunetto M, Cornberg M, Chan HL. Reply to: "Serum HBsAg kinetics in clinical prediction". J Hepatol 2017;67:193-4. [PMID: 28315711 DOI: 10.1016/j.jhep.2017.03.002] [Reference Citation Analysis]
|
| 59 |
Jeng WJ, Liaw YF. Serum HBsAg kinetics in clinical prediction. J Hepatol 2017;67:192-3. [PMID: 28315712 DOI: 10.1016/j.jhep.2017.01.036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 60 |
Hung CH, Wang JH, Lu SN, Hu TH, Lee CM, Chen CH. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat 2017;24:599-607. [PMID: 28130815 DOI: 10.1111/jvh.12683] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 61 |
Höner Zu Siederdissen C, Maasoumy B, Cornberg M. What is new on HBsAg and other diagnostic markers in HBV infection? Best Pract Res Clin Gastroenterol 2017;31:281-9. [PMID: 28774410 DOI: 10.1016/j.bpg.2017.04.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 62 |
Abdul Basit S, Dawood A, Ryan J, Gish R. Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection. Expert Rev Clin Pharmacol 2017;10:707-16. [PMID: 28460547 DOI: 10.1080/17512433.2017.1323633] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 63 |
Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 64 |
Tseng TC, Kao JH. Elimination of Hepatitis B: Is It a Mission Possible? BMC Med 2017;15:53. [PMID: 28292309 DOI: 10.1186/s12916-017-0820-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 65 |
Peng C-Y, Lai H-C, Su W-P, Lin C-H, Chuang P-H, Chen S-H, Chen C-H. Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B. Sci Rep. 2017;7:42879. [PMID: 28220833 DOI: 10.1038/srep42879] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 66 |
Zhang L, Zhang FK. Recent advances in treatment of chronic hepatitis B with entecavir. Shijie Huaren Xiaohua Zazhi 2017; 25(1): 7-16 [DOI: 10.11569/wcjd.v25.i1.7] [Reference Citation Analysis]
|
| 67 |
Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, Liaw YF. Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1813-1820.e1. [PMID: 27404969 DOI: 10.1016/j.cgh.2016.07.002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 68 |
Lee HW, Park JY, Ahn SH. An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Rev Gastroenterol Hepatol 2016;10:177-86. [PMID: 26610256 DOI: 10.1586/17474124.2016.1125781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 69 |
Hadziyannis SJ. Predicting Outcomes of Patients With Chronic Hepatitis B Virus Infection Based on Quantification of the Hepatitis B Surface Antigen. Clin Gastroenterol Hepatol 2016;14:1499-501. [PMID: 27339695 DOI: 10.1016/j.cgh.2016.06.015] [Reference Citation Analysis]
|
| 70 |
Hsu YC, Mo LR, Chang CY, Wu MS, Kao JH, Wang WL, Yang TH, Wang CS, Chiang MF, Chen CC, Fang YJ, Hung HW, Wu CY, Lin JT. Association Between Serum Level of Hepatitis B Surface Antigen at End of Entecavir Therapy and Risk of Relapse in E Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1490-1498.e3. [PMID: 27018299 DOI: 10.1016/j.cgh.2016.03.024] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 71 |
Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 72 |
Rajbhandari R, Chung RT. Treatment of Hepatitis B: A Concise Review. Clin Transl Gastroenterol 2016;7:e190. [PMID: 27628420 DOI: 10.1038/ctg.2016.46] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 73 |
Lin CL, Yang HC, Kao JH. Hepatitis B virus: new therapeutic perspectives. Liver Int 2016;36 Suppl 1:85-92. [PMID: 26725903 DOI: 10.1111/liv.13003] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 74 |
Qiu YW, Huang LH, Yang WL, Wang Z, Zhang B, Li YG, Su TT, Zhou HY, Xu W, Wang XD, Dai YP, Gan JH. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016;43:43-8. [PMID: 26523639 DOI: 10.1016/j.ijid.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 75 |
De Nicolò A, Bonifacio G, Boglione L, Cusato J, Pensi D, Tomasello C, Di Perri G, D'Avolio A. UHPLC-MS/MS method with automated on-line solid phase extraction for the quantification of entecavir in peripheral blood mononuclear cells of HBV+ patients. J Pharm Biomed Anal 2016;118:64-9. [PMID: 26517850 DOI: 10.1016/j.jpba.2015.10.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
